DR. MARTENS PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 88.55 GBX | +1.32% |
|
+3.70% | -0.34% |
| May. 31 | Deutsche Bank Lifts Dr. Martens PT, Keeps Rating at Hold | MT |
| May. 31 | RBC raises Centrica; Citigroup says buy BHP | AN |
| Sales 2024 | 877M 1.12B | Sales 2025 * | 837M 1.07B | Capitalization | 841M 1.07B |
|---|---|---|---|---|---|
| Net income 2024 | 69M 87.87M | Net income 2025 * | 28M 35.66M | EV / Sales 2024 | 0.96 x |
| Net Debt 2024 * | 325M 414M | Net Debt 2025 * | 337M 430M | EV / Sales 2025 * | 1.41 x |
| P/E ratio 2024 |
12.5
x | P/E ratio 2025 * |
28.4
x | Employees | 2,591 |
| Yield 2024 * |
5.86% | Yield 2025 * |
3.03% | Free-Float | 58.77% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dr. Martens plc
More news
| 1 day | +4.05% | ||
| 1 week | +1.45% | ||
| 1 month | +11.05% | ||
| 3 months | -9.66% | ||
| 6 months | -8.48% | ||
| Current year | -1.35% |
1 week
82.10
93.25
1 month
74.5093.25
Current year
62.00100.00
1 year
62.00162.00
3 years
62.00517.00
5 years
62.00521.60
10 years
62.00521.60
| Managers | Title | Age | Since |
|---|---|---|---|
Kenneth Wilson
CEO | Chief Executive Officer | 57 | 18-06-30 |
Ronald Garricks
CTO | Chief Tech/Sci/R&D Officer | 54 | 20-03-31 |
Geert Peeters
COO | Chief Operating Officer | 58 | 18-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Mason
CHM | Chairman | 64 | 15-08-31 |
Robyn Perriss
BRD | Director/Board Member | 51 | 20-12-31 |
Andrew Harrison
BRD | Director/Board Member | 54 | 23-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 746 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - | |
| 0.01% | 32 M€ | +6.87% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-03 | 88.4 | +1.14% | 181 125 |
| 24-05-31 | 87.4 | +4.05% | 3,445,260 |
| 24-05-30 | 84 | +0.12% | 6,705,075 |
| 24-05-29 | 83.9 | -1.47% | 4,267,638 |
| 24-05-28 | 85.15 | -1.16% | 3,220,818 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT
More quotes
Dr. Martens plc is a United Kingdom-based company, which designs, develops, procures, markets, sells and distributes footwear, under the Dr. Martens brand. The Company operates through three reporting segments: Europe, the Middle East and Africa (EMEA); Americas; and Americas and Asia-Pacific (APAC). Its product categories include Originals, Fusion, Kids, Casual and Accessories. The Originals category comprises boots, shoes and loafers and also included within the Originals category is the Made in England range. The Fusion category comprises platform boots and shoes, sandals, heels, and refined take downs of the Originals. Within the Kids category is the mini-me range, which includes Originals, Fusion, and Casual collections. It offers various accessories, such as shoe care, laces and socks, leather bags and small leather items. It operates in over 60 countries globally, through a range of modes: directly operated stores and ecommerce sites, wholesale partners and distributors.
Sector
Footwear
Calendar
2024-12-04
- Q2 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
0.874
GBP
Average target price
0.7498
GBP
Spread / Average Target
-14.20%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.35% | 1.07B | |
| +63.66% | 27.83B | |
| +28.53% | 10.9B | |
| +14.58% | 10.89B | |
| +16.97% | 10.71B | |
| +66.62% | 9.45B | |
| -5.88% | 7.73B | |
| +21.20% | 3.39B | |
| +66.90% | 2.96B | |
| -12.65% | 2.36B |
- Stock Market
- Equities
- DOCS Stock
